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Community acquired pneumonia causes 5,9% of deaths in elderly South Africans. Mortality 
rates are increased in those in whom initiation of therapy with an appropriate agent has been 
delayed. Whereas Mycoplasma pneumoniae and Legionella pneumophila are sensitive to the 
macrolides or tetracycline, they do not respond to the currently recommended first-line agents 
for community acquired pneumonia, penicillin or a cephalosporin. It was therefore necessary 
to assess the prevalence of exposure to these 2 organisms in the elderly in order to determine 
whether a modification in the recommendations may be justified. 
Methods 
Study population and survey 
Subjects were residents of 4 old age homes in Cape Town who were older than 60 years and 
willing to participate. Written consent was obtained, a demographic and medical history 
questionnaire was completed, and a sample of blood was drawn. 
Laboratory methods 
The indirect fluorescent antibody tests (Zeus Scientific Inc , New Jersey, USA) we
re used to 




The participation rate in this study was high, with 88,4% (677/766) taking part. S
eropositivity 
for both of these organisms was low. There were 17 participants (2, 51 % ) with antibodies
 to 
mycoplasma (IgG only in 8, IgM only in 1, and both IgG and IgM in the remaining
 8). Titres 
were low with only 1 IgM titre of 16 , and only 3 IgG titres of 64. Antibodies to Legio
nella 
were demonstrated in only 9 participants (1,33%). All these titres were 128 or abo
ve. 
Conclusions 
It is concluded that first-line therapy for community acquired pneumonia should ad
here to the 
current guidelines published by the South African Pulmonology Society. There is n
o indication 
for the routine use of agents active against Legionella or mycoplasma. Clearly, these 




Because of the low seropositivity rate, the indirect fluorescent antibody test for these 2 agent
s 
has a high specificity in this population. This may be of use in making a diagnosis in an acute 
infection 
Further studies are required to elucidate the immunological response to these organisms in 
elderly persons. A further survey should be done to determine the seropositivity rate to these
 
agents in community dwelling elderly. 
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C. INTRODUCTION 
1. COMMUNITY ACQUIRED PNEUMONIA IN THE ELDERLY 
In the United States community acquired pneumonia is the fourth most common cause of 
death in the elderly (Ebright & Rytel, 1980), while in South Africa 5,9% of all deaths in people 
over the age of 65 are due to pneumonia (Bradshaw et al, 1987). The older patient with 
pneumonia is more likely to have a severe illness with a complicated course and to require 
hospitalisation (Fein et al, 1991; Marrie et al., 1985) Mortality rates in community acquired 
pneumonia in adults vary from 12 to 15%, but are approximately doubled in the elderly 
(Venkatesan et al., 1990; Marrie et al., 1985) (Tables 1 and 2). Pre-existing co-morbid 
illnesses such as chronic obstructive lung disease, congestive heart failure, and diabetes 
mellitus, as well as a less efficient immune system (Sen et al, 1995) contribute to this increase 
in morbidity and mortality. (Note that the term "elderly" is usually used to refer to adults aged 
65 years and older, but that some authors regard age 60 or older as "elderly".) 
An aetiologic agent is identified in about 70% of community acquired pneumonias in adults, 
but in only 45% in the elderly (Marrie et al., 1985). The reported prevalence rates of different 
aetiological agents vary from one study to another (Table 1 ), from country to country (British 
Thoracic Society, 1987; Blanquer et al., 1991; Fang et al, 1990; Karalus et al., 1991; Lim et 
al, 1989), within a country (Macfarlane et al., 1982; White et al., 1981), and from one time to 
another within the same geographical area (Macfarlane et al., 1982; Woodhead and 
Macfarlane, 1987). Streptococcus pneumoniae is the most common cause in most studies 
conducted in adults and elderly populations accounting for 13 to 76% of cases, with 
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Haemophilus influenzae being the second most common cause responsible for some 8 to 28% 
(Tables 1 & 2) A high prevalence of Gram-negative infections has been noted in elderly 
subjects with pneumonia, Staphylococcus aureus being prominent in this group as well (Garb 
et al., 1978; Ebright & Rytel, 1980; Verghese and Berk, 1983). Mixed infections with more 
than one organism are more common in the elderly (Fein et al., 1991). 
Garb et al. ( 1978) compared community acquired pneumonia in the elderly with nursing home 
acquired pneumonia and found that Gram-negative infections were much more common in the 
latter group, 40% having Klebsieffa pneumoniae as compared with 9% in those living in the 
community Staphylococcus aureus was almost twice as common in the nursing home patients 
(26%) as in the community dwelling subjects (14%). In their study Streptococcus pneumoniae 
occurred in only 26% of nursing home residents with pneumonia as compared with 43% in the 
community acquired group, while Haemophilus influenzae was relatively uncommon in the 
former (6%) as compared with the latter (20%). The high mortality rate (40%) in nursing 
home patients as compared with those from the community (20%) was ascribed to the 
differences in aetiology. 
Mycobacterium tuberculosis has been shown to be a particular problem among the elderly in 
old age homes in South Africa (Morris & Nell, 1988). It may present as an acute pneumonia 
(Prout et al., 1983 ), and so infection with this organism must be considered in cases of 
community acquired pneumonia in older persons, especially if resident in old age homes. 
The variation in prevalence rates of adult pneumonia due to Legionella or mycoplasma is quite 
marked with mycoplasma being responsible for 1 to 18% of adult pneumonias, while 
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Legionella has been demonstrated in 2 to 15% (British Thoracic Society, 1987; Maartens et 
al., 1994; Macfarlane et al., 1982; Marrie et al., 1985) The role of these two organisms in the 
aetiology of community acquired pneumonia in the elderly will be discussed in some detail 
later. 
2. CLINICAL MANIFESTATIONS OF PNEUMONIA IN THE ELDERLY 
It is well recognised that pneumonia may have an atypical presentation in older patients. This 
may be a major factor leading to a delay in diagnosis, thus contributing to the increased 
morbidity and mortality that has been noted in these patients 
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Typical symptoms of pneumonia are less frequently elicited in patients who are of advanced 
age or have chronic illness, and may be completely absent in about 10% (Harper & Newton, 
1989) The presence of cognitive impairment contributes to this by making an accurate history 
more difficult to obtain. Alteration in mental status may be a presenting feature, and may be 
due to the development of an acute confusional state or a deterioration in cognitive function as 
compared with baseline status as a result of the infection. Acute confusion was present in the 
majority ( 65%) who died in the study by Starczewski et al. (1988). The development of 
weakness, a decline in physical function, falls, or gastro-intestinal symptoms may alert the 
physician to the possibility of pneumonia (Harper & Newton, 1989). 
There may be no fever at the time of presentation. Marrie et al. (1985) in 138 patients with 
community acquired pneumonia showed that 5 7% of those over the age of 65 were apyrexial 
at presentation as compared with 27% under 65. Likewise, cough is not necessarily a 
prominent feature in the elderly patient with pneumonia, and may be absent in approximately a 
third (Harper & Newton, 1989). 
An elevation of the respiratory rate is a subtle sign of pneumonia which may precede other 
clinical findings by some 3 to 4 days (McFadden et al., 1982). A tachycardia greater than 100 
is present at some time in about 60% with pneumonia, and is the presenting feature in 15% 
(Harper & Newton, 1989). Leucocytosis is absent in about a third. However, Harper and 
Newton (1989) noted that, even in those patients who have no symptoms to suggest a 
diagnosis of pneumonia, some abnormality suggesting infection, such as an elevated 
temperature or white cell count, was usually present 
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The typical signs of segmental or lobar consolidation of the pneumonic lung, such as dullness 
to percussion or bronchial breathing, are infrequently elicited in older patients (Berk et al., 
1982) In approximately 25% with documented pneumonia, the breath sounds are entirely 
normal, while clinical signs in areas of radiographic abnormality are detected in only a quarter 
(Osmer & Cole, 1966). To add to the diagnostic confusion is the fact that crackles may be 
present in elderly persons who do not have pneumonia or cardiac failure. This may be due to 
closure oflower zone airways which occurs during normal resting ventilation (Holland et al., 
1968). 
The rate of radiographic resolution decreases with increasing age. In the British Thoracic 
Society study ( 1987) of community acquired pneumonia, the chest radiograph had returned to 
normal in 50% of those aged 33 to 53 years by 4,5 weeks, while 9 weeks were required for a 
similar improvement in those aged 65 to 74 years. 
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3. ATYPICAL PNEUMONIA 
The term "atypical pneumonia" was first used by Reimann in 1938 to describe a group of 
patients with clinical pneumonia which was unlike the pneumonia caused by the usual 
bacterial pathogens or by the influenza virus (Reimann, 193 8). No causative agent for this 
syndrome could be identified at that time. Cold agglutinins were discovered in the sera of 
some of these patients in 194 3, and, in 1961, Channock was able to show that this syndrome 
was due to the agent which later became known as l'v!ycop!asma pneumoniae (Channock et 
al., 1961). Subsequently the term "atypical pneumonia" has come to include pneumonias due 
to Chlamydia psittaci, the Legionelfa species, and Coxie/fa bumetii, as well as the more 
recently identified organism, Chlamydia pneumoniae. 
Yung et al. (1987) feel that the term "atypical pneumonia" should not be used as a collective 
term for pneumonia caused by these organisms, nor should it be synonymous with non-
pneumococcal or non-bacterial pneumonia. Their view is that it merely describes a clinical 
pattern that can be seen with acute pneumonia caused by most aetiologic agents, and that 
pneumococcal and other bacterial pneumonias may, in some instances, present with clinical 
features not unlike those of Mycoplasma pneumoniae pneumonia. Similarly, patients with 
pneumonia due to one of the agents of the atypical pneumonia syndrome may have a clinical 
pattern identical with that of typical bacterial pneumonia. Likewise, this term has no value in 
describing pneumonia in elderly or immunocompromised patients as pneumonia due to the 
pneumococcus or other bacteria frequently present with atypical clinical features in such 
patients. A similar clinical picture may be produced by other agents such as influenza or 
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tuberculosis, or by non-infectious pulmonary conditions such as collagen-vascular disorders or 
malignancy (Yung et al., 1987). 
Several features tend to be seen more often with the atypical pneumonia syndrome. These 
pneumonias usually have a subacute onset with a dry cough and accompanying constitutional 
symptoms, and tend to have patchy rather than the more usual lobar consolidation. There may 
be marked disparity between the clinical signs and chest X-ray features, and the white cell 
count may be normal. Because sputum tends to be scanty and show little in the way of 
organisms, the diagnosis may be missed unless the possibility of one of the atypical 
pneumonias is considered and special media used or specific serology done. 
Of major clinical importance is the fact that pneumonias due to this atypical group do not 
respond to treatment with the usual antibiotics prescribed for bacterial pneumonias such as the 
penicillins or cephalosporins. However, mycoplasmal pneumonia is often a self-limited illness 
and complete recovery may occur in the absence of antibiotic therapy (Murray et al., 1975; 
Luby, 1991 ). Dual infections with more than one organism are well described, and additional 
infecting agents responsive to the above antimicrobials may be demonstrated together with 
mycoplasma or Legionella, most commonly Streptococcus pneumoniae or Haemophilus 
influenzae (British Thoracic Society, 1987; Lim et al., 1989). 
Previous studies have shown that about 20% of community acquired pneumonias are caused 
by one of the agents responsible for the atypical pneumonia syndrome (Table 3). The role of 
Chlamydia pneumoniae in community acquired pneumonia is not known as there has been no 
commercially available test for it until recently. A recent survey at Groote Schuur Hospital has 
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shown that 3 5, 9% of adults with community acquired pneum
onia who were admitted to 
hospital had primary atypical pneumonia, the most common
 organisms being Chlamydia 
pneumoniae (20, 7% ), Legionella pneumophila (8, 7% ), and M
ycoplasma pneumoniae ( 1, 1 % ) 
(Maartens et al., 1994). However, as will be seen later, myco
plasmal infection occurs in 
cycles, and it is not known whether this study was performed
 during an epidemic or 
interepidemic period. 
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4. MYCOPLASMA PNEU1WONIAE 
4.1 Introduction 
The mycoplasmas are the smallest known free-living micro-organisms with a particle diameter 
of about 300nm. They lack a cell wall thus making them deformable and able to pass through 
filters that exclude bacteria (Luby, 1991) The mycoplasma of chief importance in human 
disease is Mycoplasma pneumoniae. It attaches itself to the epithelial cell membrane via 
adherence protein or adhesin, but is, however, unable to penetrate the epithelial layer. 
4.2 Epidemiology 
Infections with Mycoplasma pneumoniae occur throughout the year with peaks during autumn 
and early winter (Luby, 1991 ). The disease is cyclical with epidemics occurring every 3 to 4 
years. During these the incidence of disease doubles Epidemics ,vere demonstrated in the UK 
in 1974-1975, 1978-1979, and 1982-1983. The British Thoracic Society study (1987) of 
community acquired pneumonia was conducted during the 1982-1983 epidemic, while the 
Bristol study (White et al, 1981) extended from 197 4 to 1980 and included 2 epidemic 
periods. Prevalence rates of mycoplasma as a cause of community acquired pneumonia during 
these studies were 18% and 14% respectively. In contrast, the study by Macfarlane et al. 
(1982) in Nottingham demonstrated only a 2% prevalence This was conducted in 1980 and 
1981 and so fell into an interepidemic period. 
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Spread is from person to person by infected respiratory droplets. Close contact is essential, 
and spread usually occurs within families or other closed populations such as college students 
or military recruits living in dormitories (Luby, 1991) 
Infection may be asymptomatic, or may produce respiratory disease with or without 
pneumonia Up to 35% of pneumonias treated on an out-patient basis are due toMycoplasma 
pneumoniae, as are up to 18% of community acquired pneumonias requiring hospitalisation 
(Luby, 1991) (Table 3). In closed populations, the figure may be as high as 50% (Mansel et 
al., 1989). However, the true prevalence of Mycoplasma pneumoniae pneumonia is not 
known, and is probably underestimated because asymptomatic infections lead to a higher level 
of background exposure than is obvious from looking at pneumonia data (Levine & Lerner, 
1978). Respiratory symptoms are minimal in about 77% who are infected with mycoplasma, 
while the disease is asymptomatic in a further 20% (Clyde, 1993). As a result, confirmatory 
evidence of pneumonia is usually not sought 
Fernald et al. ( 1975) detected serological evidence of mycoplasmal infection in 20 of 27 
children who were asymptomatic, while Foy et al. (1983) were able to demonstrate a rise in 
antibodies suggestive of reinfection in 23 cases with previous mycoplasmal pneumonia. Only 3 
of these (13%) had had symptoms of a pneumonia-like illness. 
There is little information as to the prevalence of Mycoplasma pneumoniae pneumonia in the 
elderly, and the proportion of cases with mycoplasmal pneumonia who are older varies from 
one study to another (Table 4). However, it is evident that it is not common in older persons, 
and that the bulk of cases occur in persons under 40 years (Foy et al., 1970). Carr et al. (1991) 
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found only 1 case in 127 consecutive admissions (0,8%) with acute lower respiratory tract 
infection aged 65 years and older. Only 9% of the patients with Mycop/asma pneumoniae 
pneumonia reported by Marrie (1993) were 65 years or older, while only 18% (7/39) in the 
study by Ali et al. (1986) were over the age of 60 (Table 4). Mycoplasmal pneumonia is 
primarily a..disease of schoolchildren and young adults with rates highest between 5 and 14 
years (Foy et al., 1979). A smaller peak occurs in females in the 30 to 39 year age group, most 
of whom are mothers of schoolchildren (Foy et al., 1979). 
The incubation period is 2 to 3 weeks. Despite appropriate antibiotic therapy, a 
nasopharyngeal carrier state may develop and mycoplasma may persist in the sputum for as 
long as 5 months following infection (Ali et al., 1986; Levine & Lerner, 1978; Foy, 1993). 
This means that in populations previously infected there are reservoirs of infection who are 
able to continue to spread the organism. This is prolonged in subjects with immune deficiency 
(Foy, 1993 ). The carriage rate in healthy populations varies, and tends to depend on whether 
the study is done during an epidemic or non-epidemic period. Throat swabs done on 23 54 
healthy schoolchildren showed that 3 (0, 13%) were positive for mycoplasma (Foy et al., 
1971 ). All 3 had had a recent mild respiratory illness. During epidemics in the military the 
carriage rate has been shown to be as high as 10%. Throat swabs done on healthy volunteers 
in Sweden who attended a clinic for vaccination for foreign travel showed a positivity rate of 
13,5% during an epidemic period, but only 4,6% in a non-epidemic period (9,9% overall) 
(Gnarpe et al., 1992). 
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4.3 Immunology 
The first antibodies to appear following infection with Mycop/asma pneumoniae are IgM 
immunoglobulins. They reach a peak some 10 to 30 days after the onset of symptoms, and 
then decline to become negative within about 3 months (Moule & Caul, 1987; Baum, 1995). 
IgM antibodies in the serum are thus indicative of acute or recent infection (Smith, 1986; 
, Moule & Caul, 1987). However, in older persons IgM production is decreased or absent 
(Moule & Caul, 1987; Uldum et al., 1992), and may relate to the fact that the organism has 
been encountered before and that the current infection is due to reinfection rather than to a 
primary infection (Uldum et al., 1992). 
IgG appears after IgM during the course of the first acute infection and may persist for as long 
as 3 years (Foy et al., 1983). Subsequent episodes ofmycoplasmal infection are possible, and, 
during these, IgG levels rise (Jacobs, 1993). Thus, elevated levels ofigG may indicate 
previous infection (Smith, 1986) and may be detected in individuals who are well with no 
symptoms (Smith, 1986; Uldum et al., 1992). However, IgG may also suggest a current or 
recent reinfection as both IgG and IgA may rise in such circumstances without a 
corresponding rise in Igi\1 (Jacobs, 1993 ). 
The decline of serum antibody levels is more rapid in those who have milder disease (Foy et 
al., 1983 ), and is slower in young adults than in the very young ( <5 years). Immunity is, 
however, not permanent and wanes with time. It is probably reinforced by subsequent episodes 
of infection which have been documented at 4 to 10 year intervals. 
18 
The well-known anti-I cold agglutinins are IgM antibodies directed against the I antigen on 
red cell membranes and fix complement at reduced temperatures (Levine & Lerner, 1978). 
They appear within the first 2 weeks after the onset of pneumonia in some 30 to 70% of cases 
(Luby, 1991; Murray et al., 1975). 
4.4 Clinical manifestations 
The manifestations of Mycop/asma pneumoniae infection may be respiratory or non-
respiratory. Pneumonia is the most important and well-recognised, and is thought to occur in 
some 3 to 10% of individuals infected withM pneumoniae (Mansel et al., 1989; Foy et al., 
1971). The exact incidence is difficult to determine for, while the illness may be a severe one 
resulting in death from respiratory failure, it is usually mild, subtle and self-limiting leading 
fewer than 10% to seek medical attention (Mansel et al., 1989; Dular et al., 1987). About 5 to 
l 0% require hospitalisation, although the rate may be as high as one third in some centres 
(Mansel et al., 1989). 
Most patients who become infected with Mycoplasma pneumoniae are previously healthy, 
with no well-recognised conditions, other than Down's syndrome, leading to an increased 
susceptibility to mycoplasmal infection (Baernstein et al., 1965). In the study by Mansel et al. 
(1989) only 15,5% had pre-existing medical problems, although the illness may be more severe 
in those who have chronic lung disease (Cherry et al., 1971; McNamara et al., 1969). The 
mortality due to mycoplasmal pneumonia is low with rates varying from Oto 5% (Table 5). 
This good prognosis may largely be due to the fact that it is the young and healthy who are 
most often affected. 
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4.4.1 Respiratory disease 
In most clinically apparent cases of mycoplasmal infection there is a febrile upper respiratory 
tract illness without pneumonia. Sore throat is often the initial manifestation (Luby, 1991) and 
follows an-incubation period of 12 to 14 days (Levine & Lerner, 1978). This is accompanied 
by constitutional symptoms of headache, fever, malaise and anorexia (Levine & Lerner, 1978). 
Otitis media and otitis externa may occur. Bullous myringitis is considered to be an infrequent 
manifestation, but was present in 18% in one series (Mansel et al., 1989). 
Cough is the most prominent symptom in mycoplasmal pneumonia occurring in about 95% of 
cases (Mansel et al., 1989). It is usually non-productive, but small amounts of sputum may be 
produced. This is purulent in about a third (Murray et al., 1975). Gram-stain of the sputum 
reveals many polymorphonuclear leucocytes but no predominant organism (Murray et al., 
1975; Luby, 1991), mycoplasma being too small to be detected by light microscopy (Mansel et 
al., 1989). This may be a useful pointer alerting the physician to suspect the diagnosis of 
Mycoplasma pneumoniae pneumonia (Murray et al., 1975). Haemoptysis is rare. Dyspnoea 
and wheezing may occur, and exacerbation of asthma and of chronic obstructive pulmonary 
disease are well described (Mansel et al., 1989). Pleuritic pain is uncommon (Niurray et al., 
1975). 
Auscultation of the chest usually reveals crackles and wheezes, but clinical features of 
consolidation are generally absent (Luby, 1991; Mansel et al., 1989; Murray et al., 1975; 
Levine & Lerner, 1978). There is no characteristic pattern on chest radiograph. Patchy 
alveolar infiltrates or reticular infiltrates or both may be seen (Luby, 1991 ), with a predilection 
for the lower lobes (Mansel et al., 1989). Lobar consolidation is uncommon (Luby, 1991; 
Mansel et al., 1989). Hilar adenopathy may be present, and small pleural effusions can be 
demonstrated in up to 20% in lateral decubitus views (Mansel et al., 1989). 
4.4.2 Extra pulmonary manifestations 
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Cold agglutinins are the most common extrapulmonary manifestation observed (Ali et al., 
1986), and may cause haemolysis although this is seldom clinically significant. 
Characteristically, the haemolysis occurs 2 or 3 weeks after the onset of symptoms, and 
coincides with recovery from pneumonia and the peak cold haemagglutinin titre (Murray et al., 
1975). Severe haemolytic anaemia is rare, and may be associated with haemoglobinuria., renal 
failure, and even death (Levine & Lerner, 1978). 
Neurologic manifestations were first described in the initial report of primary atypical 
pneumonia in 193 8, and occur in about 7% of patients with mycoplasmal infection requiring 
hospitalisation (Ali et al., 1986; Levine & Lerner, 1978). The features include aseptic 
meningitis, encephalitis, brachial plexus neuropathy, transverse myelitis, mononeuritis 
multiplex, Guillain-Barre syndrome, and bilateral sensorineural hearing loss (Luby, 1991: 
Murray et al., 1975; Levine & Lerner, 1978). Neurologic symptoms usually have their onset 
within 14 days of the respiratory symptoms, and do not correlate with the severity of the 
mycoplasmal infection. Recovery is usually complete, but may take as long as 5 months. The 
development, severity and duration of neurologic features do not appear to be influenced by 
antibiotic therapy (Murray et al., 1975). 
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Cardiac disease occurs in about 4,5% with mycoplasmal infection (Ali et al., 1986; Ponkii, 
1979). Rhythm disturbances, as well as ST-T wave changes on ECG, may occur. Pericardial 
effusions have been described, and, rarely, dilated cardiomyopathy with left heart failure 
(Luby, 1991). 
There may be hepatomegaly (Luby, 1991) together with mild elevation of transaminases and 
alkaline phosphatase (Levine & Lerner, 1978). Splenomegaly has been described, as have 
glomerulonephritis and acute pancreatitis (Luby, 1991 ). Generalised lymphadenopathy is rare 
( . .\li et al., 1986; Murray et al., 1975). Gastrointestinal symptoms of anorexia, nausea, 
vomiting and diarrhoea are common (Murray et al., 1975). 
Skin rashes are reported in up to 25% (Murray et al., 1975; Levine & Lerner, 1978), and 
include macular, petechial, morbilliforrn, and papulo-vesicular rashes, as well as erythema 
nodosum and urticaria (Murray et al., 1975). Erythema multiforme may occur, and the 
Stevens-Johnson syndrome has been reported in up to 4% (Ali et al., 1986). Dermatologic 
manifestations develop within 2 weeks of the onset of respiratory illness, and may persist long 
after the pulmonary features have resolved (Murray et al., 1975). It has been suggested that 
certain antibiotics may precipitate the development of rashes in mycoplasmal infection in much 
the same way that ampicillin does in infectious mononucleosis (Ali et al., 1986; Levine & 
Lerner, 1978). 
Nonspecific myalgias and arthralgias occur in 15 to 45% (Murray et al;., 1975; Cassell, 1981). 
There may be an inflammatory arthritis mainly involving large joints which is migratory and 
polyarticular (Ali et al., 1986; Murray et al., 1975). This coincides with the acute illness, is 
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transient, and resolves with recovery from the respiratory infection. The joint manifestations 
may pose a diagnostic problem causing confusion with acute rheumatic fever or rheumatoid 
arthritis. 
4.5 Clinical course 
Mycoplasmal pneumonia is usually self-limited, and most patients make a complete recovery 
(Murray et al., 1975; Luby,1991). Fever, headache and malaise resolve in 3 days in untreated 
cases, whereas chest signs take longer to disappear paralleling radiological clearing. X-ray 
features may resolve in 10 to 21 days, but complete resolution can take up to 6 weeks (Murray 
et al., 1975). There have been reports of chronic pulmonary sequelae with progressive fibrosis, 
bronchiectasis, bronchiolitis obliterans or organising pneumonia following mycoplasmal 
pneumonia (Luby, 1991 ). Although appropriate antibiotic therapy does not eradicate the 
organism from the respiratory tract, the duration of symptoms is decreased and resolution of 
radiological abnormalities is accelerated (Murray et al., 1975). 
The disease is rarely fatal, but may occasionally be serious and life threatening (Table 5). In 
the British Thoracic Society study ( 1987) the mortality rate of those patients with 
1vfycoplasma pneumoniae pneumonia was 4. 9%. All were given appropriate antibiotics after 
admission, although not before. 
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4.6 Mycoplasmal pneumonia in the elderly 
The fact that the elderly have more chronic disease than younger patients does not appear to 
put them at greater risk for developing mycoplasmal pneumonia. It is not known whether the 
complication rate increases with age, nor whether mortality is increased by age, although 
neither seems to be the case. No studies have assessed long-term morbidity, although it would 
appear that complete recovery is the norm, even in the elderly. 
Marrie (1993) reported on 64 patients with mycoplasmal pneumonia who required 
hospitalisation. Of these, 58 (90,6%) were aged 64 or younger (mean 37,3 years), while 6 
(9,4%) were 65 or older (mean 78,3 years). The mean number of underlying diseases was 
more than three times greater in the older group (3,0 as compared with 0,9), and the mean 
length of hospital stay was two and a halftimes greater (30 as compared with 11,7 days). 
Despite these features which would suggest the contrary, the proportion who developed 
complications was similar in the 2 groups: 10 ( 17 ,2%) in the younger group and 2 ( 17%) in 
the older group. These included respiratory failure requiring ventilation, pulmonary 
haemorrhage, haemolysis, thrombocytopenia, cerebra-vascular accident, and Guillain-Barre 
syndrome. In this study only 1 death occurred, and this was in a 51 year old man with Shy-
Drager syndrome who had recovered from his pneumonia and died from his underlying 
disease. 
There were 3 9 patients with mycoplasmal pneumonia in the study by Ali et al. ( 1986). Of these 
7 (18%) were older than 60 years. Only 3 had significant complications: a teenage boy 
developed Stevens-Johnson syndrome, and a 67 year old man developed sensorineural 
deafness. Both recovered. The third was a 3 8 year old woman with Down's syndrome who 
died. She had severe multilobe pneumonia, pleural effusion, pericardial effusion, and 
haemolytic anaemia. 
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Mansel et al. (1989) report on 148 patients with Mycoplasma pneumoniae pneumonia, 14 
(9,5%) of whom were older than 40. Prior or co-existing medical problems were present in 23 
(15,5%) and 49 (33%) developed extrapulmonary manifestations. Unfortunately, the ages of 
these subjects are not mentioned. Complications were rare with I man (age not given) 
developing adult respiratory distress syndrome from which he made an uneventful recovery. 
The only death was in a 3 month old baby with mixed immunodeficiency who died following 
open lung biopsy and in whom concurrent infection with both Mycoplasma pneumoniae and 
Nocardia asteroides was demonstrated. 
These studies would suggest that, despite the fact that older patients are more likely to have 
underlying disease, their complication rate and mortality from mycoplasma pneumonia is no 
greater than in younger patients. They may, however, take longer to recover and may require a 
longer period of hospitalisation. The fact that these studies were conducted in hospitalised 
patients may have made the numbers of elderly disproportionately high, as older patients and 
those with co-morbid illness are more likely to be hospitalised than are younger patients with 
disease of the same severity. The lack of demonstration of more adverse outcomes in the older 
patients, therefore, underlines even more strongly the relatively benign nature of this disease. 
4. 7 Diagnosis 
Most authorities would agree that culture of mycoplasma in the sputum constitutes definite 
evidence for current infection (Ali et al., 1986; Foy et al., 1971; Levine & Lerner, 1978). 
However, .Gnarpe et al. (1992) in Sweden were able to demonstrate that 9,9% of healthy 
adults attending a clinic for vaccination for foreign travel had positive mycoplasmal cultures 
from throat swabs, although very few had any history of recent respiratory infection. 
25 
Serological diagnosis of acute infection is based on the demonstration of a fourfold or greater 
rise in antibody titre between paired acute and convalescent sera using any of the available 
serologic tests (British Thoracic Society, 1987). A single titre ~4 (British Thoracic Society, 
1987) or >16 (Maartens et al., 1994) for mycoplasmal IgM is considered definite evidence of 
acute infection. A single titre in a convalescent specimen ~64 for the mycoplasmal specific IgG 
indirect fluorescent antibody test is considered evidence of probable infection (Maartens et al., 
1994). 
Cold haemagglutinins (anti-I IgM) appear during the first or second week in mycoplasmal 
infections, but are found in only 30 to 70% of cases (Luby, 1991; Murray et al., 1975) so that 
a negative test is not of much value (Jacobs, 1993 ). A single titre ~64 or a fourfold rise in 
paired sera 25 days apart is considered evidence of acute infection. A low cold agglutinin titre 
<64 may be due to infection with viruses such as adenovirus, respiratory syncytial virus, 




Treatment of infection with Mycoplasma pneumoniae is often empiric and based on clinical 
suspicion before the diagnosis is confirmed. Antibiotics are not usually necessary for 
mycoplasmal upper respiratory infections. However, although Mycoplasma pneumoniae 
pneumonia is a self-limiting illness which is seldom life-threatening, effective antibiotic therapy 
may markedly decrease the duration of the illness and, in doing so, decrease spread. 
Erythromycin and tetracycline are the agents that have been most extensively used against 
Mycoplasma pneumoniae. They are equally effective clinically and have come to be regarded 
as the drugs of choice (Yung et al., 1987; Rasch & Mogabgab, 1965), although neither is 
mycoplasmacidal (Mansel et al., 1989). Because mycoplasma lacks a cell wall, it is resistant to 
the beta-lactam antibiotics such as the penicillins and the cephalosporins. Both erythromycin 
and tetracycline have been shown to shorten the duration of fever and hospitalisation, and to 
hasten the resolution of radiological changes (Rasch & Mogabgab, 1965). They do not, 
however, eradicate the organism from the respiratory tract, and cultures of the nasopharynx 
and sputum may remain positive for weeks to months (Smith et al., 1967). This may relate to 
the fact that, although mycoplasma is an extracellular organism and adheres to the 
endobronchial epithelium, it is able to reside intracellularly as well. The efficacy of antibiotics 
in controlling the extrapulmonary manifestations is not known (Mansel et al., 1989; Cassell & 
Cole, 1981; Murray et al., 1975). 
Most patients become afebrile within 48 hours of commencing therapy. There is no consensus 
on the optimal duration of therapy for Mycoplasma pneumoniae pneumonia, but most treat for 
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2 to 3 weeks to avoid relapse which may occur in 10% (Cotton et al., 1987; Yung et al., 1987; 
Baum, 1993). The total daily dose of erythromycin or tetracycline for adults is l-2gm. 
Erythromycin has a high incidence of gastro-intestinal side-effects and may be poorly 
tolerated. The use of tetracycline is precluded in young children because of its adverse effect 
on develo{ling teeth and bone. Doxycycline is better tolerated than tetracycline, and should be 
given in a dose of 100-200mg per day (Yung et al., 1987). Therapeutic failures with both 
erythromycin and tetracycline have been reported, and it is suggested that therapy with the 
alternate agent be instituted if there has been no improvement within 5 to 7 days of therapy 
(Ford et al., 1980). 
The newer macrolides, clarithromycin and azithromycin, have also been shown to be active 
against mycoplasma. They have several advantages over erythromycin, with better oral 
absorption and fewer gastro-intestinal side-effects (Neu, 1992; Wood, 1991; Peters & 
Clissold, 1992). 
A1ycoplasma pneumoniae is susceptible to the quinolones, although they are expensive and not 
as effective as the macrolides (Waites et al., 1988). They are also relatively contra-indicated in 
children due to their adverse effect on weight-bearing joints in the young. 
Steroids have been used in conjunction with antibiotic therapy and appear to be useful in 
patients with severe pneumonia and erythema multiforme. However, controlled prospective 
studies are needed to assess their true value (Levine & Lerner, 1978). 
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5. LEGIONELLA PNEUMOPHILA 
5.1 Introduction 
Legionel!Q.pneumophila was probably first isolated in 1947, when the organism was 
recovered from the blood of a patient with a febrile respiratory illness using guinea pig 
inoculation (McDade et al., 1979). An outbreak was associated with a meat packing plant in 
1957 (Osterholm et al., 1983) and another in a Washington psychiatric hospital in 1965 
(Eickhoff, 1979). However, it was not until July 1976 when an outbreak occurred in 
Philadelphia during a convention of the American Legion that attention was drawn to the 
infection and it was given the name Legionnaires' disease (Fraser et al., 1977). The causative 
organism was isolated from the lung tissue of four fatal cases in January 1977 (McDade et al., 
1977), and was subsequently named Legionella pneumophila (Brenner et al., 1979). 
5.2 Microbiology 
Legionella pneumophila is a fastidious non-acid-fast bacillus which is an obligate aerobe and 
stains very poorly with the Gram stain. It does not grow on standard bacteriologic media 
(McDade et al., 1977; Isenberg, 1979), but will grow on buffered charcoal yeast extract agar. 
These features cause some difficulty in diagnosis using routine techniques. 
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5.3 Epidemiology 
The Legionel/a species are ubiquitous water micro-organisms which grow best in stagnant 
water, especially if it is warm (Edelstein & Meyer, 1984). They have been isolated from many 
aquatic sources including fresh water lakes, plumbing fixtures, air conditioning systems, and 
distribution systems for drinking water (Edelstein & Meyer, 1984; Nguyen & Yu, 1991). 
Both sporadic and epidemic forms of infection with Legionella occur, the latter being 
described in public buildings such as hotels or hospitals where infection has, in some instances, 
been traced to a point source (England et al., 1981 ). An association with travel and with 
exposure to construction and excavation has been noted. Spread is by aerosolisation of 
contaminated water via air conditioning systems, showerheads or nebulisers (Meyer, 1984). In 
an outbreak in a Johannesburg hospital (Strebel et al., 1988) ventilators were thought to have 
played a role in the spread of infection. Person to person spread does not occur (Nguyen & 
Yu, 1991 ). There appears to be seasonal variation in Legionel/a infection with a summer-
autumn predominance (Eickhoff, 1979). The reason for this is uncertain, one explanation given 
being that air conditioning systems are used more extensively in summer (England et al., 
1981 ). 
Infection with Legionella may occur at any age, but is more common in the elderly with a 
peak incidence over the age of 60 (Cotton et al., 1987). It is exceedingly uncommon in 
children. Other than age, risk factors for infection include male sex, smoking, alcoholism, 
diabetes, chronic cardiopulmonary disease. and immunosuppression (Davis et al., 1981; Fraser 
et al., 1977; Gump et al., 1979; Eickhoff, 1979). The attack rate in recipients ofrenal or bone 
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marrow transplants is especially high (Edelstein & Meyer, 1984). However, patients with 
neutropenia or AIDS do not appear to have an undue predilection for the disease (Nguyen & 
Yu, 1991). 
The reported prevalence of Legionella infection varies from one centre to another. It is the 
causative agent in 2 to 23% of community acquired pneumonias requiring hospitalisation 
(Table 3 ), being second only to Streptococcus pneumoniae in several Spanish studies 
(Blanquer et al., 1991; Pachon et al., 1990; Rello et al., 1993). The rates within an area may 
also vary, and in Nottingham, UK in 1980-1981 Legionella pneumonia constituted 15% of 
community acquired pneumonias in adults (Macfarlane et al., 1982), despite a low background 
antibody titre in the population and despite no apparent evidence for clustering emanating 
from a single source (Macfarlane et al., 1982; Macrae et al., 1979). This high yield was 
attributed to the fact that Legionella was vigorously sought even in patients who were not 
seriously ill. Convalescent sera from all subjects were tested, thus enabling a diagnosis to be 
made which might otherwise have been missed. The high prevalence of Legionella in 
Nottingham has not persisted, however, and in the British Thoracic Society study (1987), 
which was conducted in 1982-1983, only 2 patients (5%) from Nottingham were shown to 
haveLegionella. The Bristol study (conducted from 1974 to 1980) showed a prevalence of 
only 1,5% (White et al., 1981). Legionella was not sought in the early years of this particular 
study as it only became recognised as a distinct entity following the outbreak in Philadelphia in 
1976 (Fraser et al., 1977), and sera for testing for antibodies to Legionella only became 
available from that time onwards (White et al., 1981 ). Similarly, 9% of cases of community 
acquired pneumonia admitted to Groote Schuur Hospital during 1987-1988 had Legionella 
pneumophila pneumonia (Maartens et al., 1994), but no cases had been identified in the same 
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hospital in a 6 month period during 1980 (Prout et al., 1983). The prevalence ofnosocomial 
infections due to Legionella may be as high as 30% (Meyer, 1984). 
5.4 Clinical manifestations 
Legionella pneumophila is best known as the cause of Legionnaires' disease, an acute 
pneumonic illness. However, together with other species of the genus Legionella, it may also 
cause a non-pneumonic illness, Pontiac fever, or may be responsible for subclinical infection 
(Glick et al., 1978; McDade et al., 1977). 
Silent or subclinical disease is probably the most common form of Legionella pneumoniae 
infection (Marik, 1989), and this may be inferred from the presence of antibodies to 
Legionella pneumophila in individuals who are totally asymptomatic (Kirby et al., 1980). 
Pontiac fever is an acute self-limiting febrile illness that derives its name from the first 
recognised outbreak which occurred in the health department in Pontiac, Michigan in 1968 
( Glick et al., 1978). It is a flu-like illness with high fevers, myalgia, headache and malaise, and 
develops 1 to 2 days post exposure. Pneumonia does not occur (McDade et al., 1977; Kirby et 
al., 1980), and complete recovery within 1 week is the norm. Diagnosis is based on 
documentation of seroconversion, as the organism has never been isolated from affected 
individuals. 
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5.4.1 Legionnaires' disease 
The incubation period for Legionnaires' disease is 2 to 10 days (Swartz, 1979). Early 
symptoms are those of an influenza-like illness with malaise, weakness and lethargy. High 
fevers are typical, frequently accompanied by rigors. Unlike mycoplasmal pneumonia, upper 
respiratory tract symptoms are usually absent (Tsai et al., 1979). Cough is present in 87% 
(Kirby et al., 1980), but is not a prominent feature early in the disease. It is usually non-
productive, but small amounts of sputum may be produced in 50% which may be purulent or 
even bloody (Tsai et al., 1979; Edelstein & Meyer, 1984). Chest pain, usually pleuritic, is 
present in about a third of patients (Swartz, 1979). 
Clinical findings in the chest are unimpressive, and usually reveal scattered crackles or 
wheezes with the later development of areas of consolidation (Tsai et al., 1979; Edelstein & 
Meyer, 1984 ). Radiologic manifestations are variable, initially being unilateral in the majority 
of cases (Swartz, 1979). Patchy alveolar infiltrates are most commonly seen, progressing to 
consolidation in about 70% (Nguyen & Yu, 1991). This may involve upper or lower zones, or 
may become bilateral (Edelstein & Meyer, 1984). Multilobar involvement has been reported in 
65% (Swartz, 1979). Small pleural effusions are present in a third of patients (Nguyen & Yu, 
1991). Cavitation is unusual (Swartz, 1979). Radiologic features tend to progress even in the 
face of adequate treatment (Muder et al., 1987), with radiologic improvement usually lagging 
behind clinical improvement and taking up to 4 months for complete clearing to occur 
(Swartz, 1979). 
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5.4.2 Extrapulmonary manifestations 
These features are believed to be the result ofbacteraemic dissemination. Gastrointestinal 
symptoms are a prominent feature in the early stages, with watery diarrhoea in about 40% 
(Tsai et al .. 1979; Kirby et al., 1980). Abdominal pain may be present, and nausea and 
vomiting occurs in about 25% (Tsai et al., 1979; Kirby et al., 1980). Mild elevations of serum 
transaminases are common (Tsai et al., 1979). 
Abnormalities of the central nervous system occur in a third of patients (Kirby et al., 1980). 
Headache is seen in 40% (Kirby et al., 1980), and confusion in 30% (Cotton et al., 1987). 
Other features include agitation, hallucinations, stupor, amnesia, grand mal seizures, 
dysarthria, ataxia, and peripheral neuropathy (Edelstein & Meyer, 1984). 
Renal abnormalities range from mild elevations of the urea and creatinine to frank renal failure 
(Tsai et al., 1979). Cardiac involvement has been described with the development of 
pericarditis or endocarditis, and episodes of culture negative endocarditis should prompt a 
search for Legionella (Nguyen & Yu, 1991 ). Relative bradycardia is common and is found in 
about 60% (Kirby et al., 1980). 
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5.5 Diagnosis 
Usually the diagnosis of acute Legionella infection is made serologically, the indirect 
fluorescent antibody test being the most widely used (Cotton et al., 1987; Edelstein & Meyer, 
1984; Ratshikhopha et al., 1990; Marik, 1989). A fourfold or greater rise in antibody titre to a 
level of at least 128 together with a compatible clinical picture is regarded as diagnostic 
(Wilkinson, 1982; Ratshikhopha et al., 1990; Cotton et al., 1987; Marik, 1989) with 
sensitivities and specificities of 70 and 95% respectively (Wilkinson et al., 1983). A single titre 
of at least 256 is considered to be presumptive evidence of infection at an unknown time, but 
is not diagnostic because of the high level of subclinical or mild infection that may exist in the 
particular population from which the patient comes (Wilkinson et al., 1982). 
The immunological response to Legionella infection may be with IgG, IgM and IgA singly or 
in various combinations. IgG and IgM titres may remain elevated for several years, but IgA 
levels are not sustained. For this reason, polyimmunoglobulin conjugates (total 
immunoglobulin titres) are used in the indirect fluorescent antibody test instead of measuring 
titres of individual immunoglobulin classes (Wilkinson et al., 1982). 
Antibody titres generally begin to rise by the third week after onset, a fourfold rise having 
occurred in most patients by week 6 (Kirby et al., 1980). However, about 20 to 30% with 
Legionnaires' disease remain seronegative (Edelstein & Meyer, 1984). It is possible that 
testing later in convalescence may demonstrate an antibody response, or that disease in these 
patients is caused by a serogroup not detected by the antigen used in the test (Kirby et al., 
1980). Antibody titres may remain elevated for at least 2 years (Lattimer et al., 1979; Tsai & 
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Fraser, 1978), even after appropriate antibiotic therapy, making it difficult to distinguish 
present from past illness (Nguyen & Yu, 1991~ Kirby et al., 1980). A further confounder is the 
fact that immunofluorescent antibody titres are not entirely specific, and cross-reactivity may 
occur with Pseudomonas and other Gram-negative bacteria, as well as Mycoplasma 
pneumoniqe and Chlamydia psittaci (Kirby et al, 1980). 
Legionella may also be cultured from respiratory secretions, but it is a slow growing and 
fastidious organism requiring special media (Edelstein & Meyer, 1984). The yield in sputum is 
less than 40%, but may be higher from transtracheal aspiration (Marik, 1989). Direct 
immunofluorescent examination for Legionella antigen in sputum or other body fluids or 
tissue is highly specific (99,9%) but only moderately sensitive (70-75%). 
5.6 Treatment 
Legionella pneumonia is a much more severe disease than mycoplasmal pneumonia with most 
patients requiring hospitalisation. The mortality rate is 15 to 20% (Edelstein & Meyer, 1984 ), 
but rates as high as 67% have been reported (White et al., 1981) (Table 5). The mortality in 
nosocomial infections may approach 50%, especially if antibiotic therapy is started late (Yu, 
1995). Mortality is greater in patients who are older or who have chronic underlying disease, 
particularly chronic bronchitis or emphysema (England et al., 1981). Early diagnosis is difficult 
(British Thoracic Society, 1987) further contributing to the adverse outcome. The mortality 
rates in immunosuppressed patients are even higher with rates up to 80% being recorded 
(Edelstein & Meyer, 1984). It is thus important that antibiotics active against Legione lla be 
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started early in all patients with community acquired pneumonia who are seriously ill and in 
whom a diagnosis of Legionella is considered. 
Erythromycin was the drug of first choice in Legionella pneumonia (Kirby et al., 1980; Gump 
et al., 1972), although this may be changing with the advent of newer agents. It was used as 
empiric therapy in the early outbreaks of Legionnaires' disease with a fourfold decrease in 
fatality rates (Edelstein & Meyer, 1984). The mortality rate in those patients who did not 
receive erythromycin was 23 to 55%, while in those in whom it was used the rate was 6 to 
13% (Beaty et al., 1978; Tsai et al., 1979; Kirby et al., 1980). Its activity against Legionella 
may be explained by the fact that erythromycin is concentrated within alveolar macrophages 
and polymorphonuclear leucocytes (Johnson et al., 1980). Erythromycin should be given in a 
daily dosage of 2gm orally or 4gm IV. However, the gastro-intestinal disturbance seen with 
Legionella may compromise absorption of the oral form. As a result, it may be necessary for 
initial treatment to be given intravenously, especially in those patients who are severely ill, and 
for oral therapy to be commenced only once clinical improvement occurs, usually within 3 to 5 
days (Yu, 1995). Treatment should be continued for at least 2 to 3 weeks to decrease the 
likelihood of relapse (Swartz, 1979; Yu, 1995). A longer duration of therapy is appropriate for 
immunosuppressed patients. 
The newer macrolides (azithromycin, clarithromycin and roxithromycin) have superior in vitro 
activity and improved pharmacokinetics when compared to erythromycin. However, they are 
much more costly and clinical trials of efficacy have yet to be performed (Yu, 1995). 
Clarithromycin appears to be the drug most active against Legionella (Peters & Clissold, 
1992). It achieves higher concentrations than erythromycin in tissues such as the lung, and its 
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ability to penetrate cells is an advantage in treating organisms which proliferate within cells as 
Legionella does (Peters & Clissold, 1992; Neu, 1992). It has also been shown to have some 
bactericidal activity against Legionella (Peters & Clissold, 1992). 
Tetracycliue has also been shown to decrease mortality, but the results have been inconsistent 
(Woodhead, 1992; Kirby et al., 1980; Cotton et al., 1987). Nguyen and Yu (1991) have 
suggested that their high lipid solubility and twice daily dosage may give doxycycline or 
minocycline an advantage over conventional tetracycline. 
In Legionella pneumonia, the organism has been shown to be concentrated within the lung 
macrophage (Nguyen & Yu, 1991). Rifampicin has been shown to be potent and highly 
effective against Legionella, no doubt due in part to the fact that it is able to penetrate the 
macrophage and achieves a high concentration within the lung (Thornsberry et al., 1978; 
Liebers et al., 1989; Moffie & Mourten, 1988). However, because of the danger of developing 
resistance, rifampicin should not be used alone, but should be reserved for use in combination 
in patients who are seriously ill (Kirby et al., 1980). 
The fluoroquinolones, ofloxacin and ciprofloxacin, are active against Legionella, and patients 
unresponsive to erythromyin have been successfully treated with ciprofloxacin. However, 
there is very little clinical data to support their use (Hooper & Wolfson, 1991; U nertl et al., 
1989). 
There is limited experience with agents such as trimethoprim-sulfamethoxazole and imipenem, 
and reports are anecdotal only (Farrell et al., 1985). 
Mortality rates are higher in patients who are immunosuppressed. Steroids have no place in 
the management of Legionella, and should be stopped wherever possible in patients already 
receiving these agents (Tsai et al., 1979). 
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6. ERYTHROMYCIN AND THE NEWER MACROLIDES 
Erythromycin belongs to the macrolide group of antibiotics (Washington & Wilson, 1985) and 
is produced by Streptomyces erythraeus. It is bacteriostatic, and binds to the SOS subunit of 
the bacterial ribosome, thus inhibiting protein synthesis (Dollery, 1991). Its spectrum of 
antibacterial activity is similar to that of penicillin giving it a particular role in patients with 
penicillin allergy. In addition, it has antibacterial activity against Legionella, mycoplasma and 
chlamydia. 
Both oral and parenteral forms exist. Oral absorption is inconsistent, and depends on various 
factors, such as the form used, gastric acidity, and the presence of food in the stomach. Once 
absorbed, it is extensively distributed into most tissues and body fluids, but is unable to 
penetrate the CSF. It is highly protein-bound (>70%) (Washington & Wilson, 1985). A small 
percentage is excreted unchanged in the urine (2,5% of oral form and 15% ofintravenous 
form). The remainder is partially metabolised in the liver by demethylation. Most is 
concentrated and excreted in active form in the bile. 
Erythromycin is responsible for several important drug interactions, and these may be 
particularly severe in older people or those with chronic disease. It inhibits the hepatic 
microsomal enzymes and thus has the potential to cause a rise in serum levels and increased 
activity of various drugs, including theophylline (Iliopoulou et al., 1982), carbamazepine 
(Wroblewski et al., 1986), warfarin (Bartle, 1990), and digoxin (Lindenbaum et al., 1981) with 
the risk of toxicity or haemorrhage. 
Gastrointestinal intolerance is prominent, with frequent complaints of nausea, vomiting, 
diarrhoea, abdominal pain or cramps. This may occur with both oral and IV preparations, 
particularly with doses greater than 4gm per day. A dose-related increase in serum 
transaminases may occur, which may recur on rechallenge with the drug. 
40 
An immunologically mediated cholestatic jaundice is well recognised but rare and manifests 
with abdominal pain, nausea, anorexia and fever. It may be associated with skin rashes, 
urticaria, eosinophilia, and an elevation in liver enzymes. Liver toxicity has been most 
commonly reported with the estolate form, but this may reflect its more widespread use rather 
than any greater toxic potential. Symptoms usually begin after 10 to 20 days of treatment, and 
disappear within days of ceasing therapy. 
Use of the intravenous form may cause local pain and irritation, or even thrombophlebitis. 
Intramuscular injection is not recommended as it is extremely painful, and sterile abscesses 
may occur. 
Reversible hearing loss is a rare complication of erythromycin therapy. It has been observed 
most often in patients given 4gm or more daily, especially in the presence of renal failure 
(Washington & Wilson, 1985; van Marion et al., 1978). 
Allergic reactions occur rarely, and include fever, rash, eosinophilia and joint pain. 
Erythromycin has been in use for more than 40 years, and is considered to be an extremely 
safe agent (Neu, 1992). However, in the last 10 or 15 years several newer macrolides have 
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been developed which do have some advantages over erythromycin (Neu, 1992; Peters & 
Clissold, 1992; Wood, 1991 ). These include clarithromycin, azithromycin, roxithromycin, 
flurithromycin, and dirithromycin. The new macrolides are more stable in acid and are thus 
better absorbed from the gastro-intestinal tract. Their tissue and intracellular concentrations 
are higher ,..and they have longer half-lives permitting longer dosing intervals than those 
required with erythromycin. More important, however, is the improved microbiological 
activity of the newer agents. Both clarithromycin and azithromycin inhibit Mycoplasma 
pneumoniae, Legionella pneumophila and Chlamydia pneumoniae at lower concentrations 
than does erythromycin. They also have activity against Haemophilus influen=ae, a property 
which is lacking in erythromycin, and are active against Mycobacterium avium. In addition, 
azithromycin is active against Toxoplasma gondii and Borre/ia burgdorferi. These drugs are 




The mortality associated with community acquired pneumonia is significant, particularly in 
elderly subjects (Tables I & 2). Institution of an appropriate antibiotic at an early stage is 
essential if this high mortality is to be reduced. Verghese and Berk (1983) have demonstrated 
improved survival rates in those in whom initial therapy was appropriate as compared with 
those in whom the use of an appropriate agent was delayed. They define "appropriate" therapy 
as that antibiotic or combination of antibiotics which is begun within 24 hours and to which 
the organism is shown to be sensitive. This requires an accurate prediction as to the most 
likely aetiologic agent. 
A knowledge of local prevalence rates of the different microbial agents causing pneumonia 
would permit empiric therapy to be tailored to local conditions. This is important for, while a 
second-generation cephalosporin has been recommended as the most suitable first-line agent 
for the treatment of community acquired pneumonia in the elderly in South Africa (SA 
Pulmonology Society, 1996), if Legionella or mycoplasma comprised a significant proportion 
of causes of pneumonia, it would be prudent to add erythromycin or one of the newer 
macrolides. In contrast, the addition of erythromycin as a routine would be unnecessary if 
local prevalence rates were low and infection with these organisms was not expected to occur 
sufficiently frequently to justify the additional expenditure. There is little information as to the 
prevalence of Legionella or mycoplasma infection in the elderly in South Africa. It would 
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therefore be helpful to know the level of exposure to these organisms in elderly subjects in our 
community. 
2. AThl 
To provide information as to the most appropriate first-line antibiotic therapy for community 
acquired pneumonia in the elderly in South Africa. 
3. OBJECTIVE 
To determine the prevalence of Legionella and mycoplasma seropositivity in the elderly in old 
age homes in Cape Town. 
4. SUBJECTS AND METHODS 
4.1 Study population 
All the residents of four old age homes in the Cape Peninsula were invited to participate in this 
study. Subjects aged 60 years and older were eligible for inclusion. The only subjects who 
were excluded were those who refused to participate, or those who were willing but from 
whom blood could not be obtained for technical reasons. No person was excluded on the basis 
of previous or current medical problems or drug therapy. 
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The four old age homes chosen were all subsidised homes belonging to the Cape Peninsula 
Organisation for the Aged, and were chosen largely because of the fact that they were fairly 
close to Groote Schuur Hospital, and therefore easily accessible. In order to make the study 
sample as representative as feasibly possible, an attempt was made to include subjects from all 
population_groups in the Cape Peninsula, including those who have historically been 
disadvantaged. However, at the time that the study was undertaken, old age homes were 
segregated accorded to colour, and there were no old age homes for black people. The homes 
visited in this study thus comprised two which housed white residents only, while the other 
two housed so-called coloured people. 
4.2 Methods 
Baseline information (including demography, health status, smoking history, functional status 
and current therapy) was obtained for each participant using the medical records as well as 
information from the nursing staff The data sheet is shown in Appendix I. 
Blood was taken from each subject and, after separation of the serum, was stored at -20°C 
until antibody titres to Legionella and mycoplasma could be determined in batches. 
The detection of antibodies to Mycoplasma pneumoniae was performed using an indirect 
fluorecent antibody technique (Zeus Scientific Inc., New Jersey, USA). Species specific 
membrane antigen was incubated with the serum to be tested, and antibody was demonstrated 
by staining with fluorescein-labelled anti-human antibody. A single IgG titre of 32 or greater 
was considered to indicate previous infection, while a titre of 64 might be indicative of current 
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or recent infection. IgM antibodies were also sought, and these were regarded as indicative of 
current or recent infection only. A single titre of 32 or greater was considered to be 
significant. 
The presel!ce of antibodies to Legionella pneumophi/a was sought using an indirect 
fluorescent antibody test (Zeus Scientific Inc., New Jersey, USA). The assay uses heat-killed 
Legionella bacteria (L. pneumophi/a groups 1 - 4) as the substrate antigen and polyvalent 
fluorescein-labelled anti-human globulin as the antibody indicator. A single titre of 128 or 
greater was considered to be positive and to indicate previous infection with Legionella. A 
titre of 256 or greater is presumptive evidence of acute or recent infection. 
4.3 Ethical considerations 
Approval for the study was obtained from the UCT Ethics and Research Committee, as well as 
from the Medical/Nursing Advisory Committee of the Cape Peninsula Organisation for the 
Aged, the managers of the four old age homes included in the study, and from the doctors 
providing medical care for the residents of the homes. Confidentiality was ensured. 
Written consent was obtained for all subjects, either from the subject him/herself, or from a 
relative, or from the Matron in charge of the old age home. Because this study required simply 
that a single blood specimen be taken, it was not felt necessary to contact a family member in 
all cases where the subject could not give consent. 
4.4 Sample size 
As all residents of the 4 old age homes who met the criteria were included, sample size was 
not determined prior to the study. This was, however, done later as an exercise using the 




There were 766 residents in the 4 homes, and 677 (88,4%) participated in the study. Of these, 
174 were males (25,7%) and 503 were females (74,3%), with a mean age of 78, 1 years (range 
60-98 yearJ). The non-respondents were too young (<60 years), or refused to participate, or 
were not in the home during that period because they were away on holiday or in hospital, or a 
blood specimen could not be obtained. 
5.1 Mycoplasma pneumoniae 
There were 17 participants (17/677 = 2,51%) with antibodies to Mycoplasma pneumoniae 
(Table 6). Of these 8 (8/l 7=47,06%) had IgG antibodies only and 1 (1/17=5,88%) had IgM 
antibodies only, while the remaining 8 (8/l 7=47,06%) had both IgG and IgM. This meant that 
IgG was present in 16 participants (16/677=2,36%) and Ig..i\1 in 9 (9/677=1,33%). 
The IgM titres were low with 1 participant ( 1/9= 1, 11 % ) having a titre of 16, while the titre in 
the remaining 8 (8/9=88,89%) was 8. The IgG titres were also low with 3 participants 
(3/16=18,75%) having titres of 64, 12 (12/16=75%) having titres of32 and the remaining 1 
(1/16=6,25%) having a titre of 8. Each of those who were positive for both IgM and IgG had 
an IgM titre of 8. The remaining participant who was IgNf positive had a titre of 16. 
IgM positivity was confined to 2 of the 4 old age homes where the investigation took place, 
there being 5 positives in one of the homes and 4 in the other. All except 3 of those who were 
IgG positive were in the same 2 homes. 
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5.2 Legionella pneumophila 
Antibodies to Legione/la pneumophila were demonstrated in only 9 (1,33%) participants 
(Table 7), 7 (78%) of whom were female and 2 (22%) of whom were male. There was no 
clustering _gf positive sera with 3 each coming from homes 1 and 2, another 2 from home 3, 
and the remaining 1 from home 4. In 6 (0,89%) the titre was 128, while in 1 (0,15%) it was 
256, and in the remaining 2 (0,29%) it was 512. The ages of those with positive titres ranged 
from 68-85, with a mean of77,l years (compared with the sample mean of78,l years). 
There were 4 with positive Legione/la serology who were smokers, while 1 was an ex-
smoker, and the remaining 4 had never smoked. Chronic obstructive airways disease had been 
diagnosed in 3, all of whom were either current or previous smokers. There were 2 subjects 
with a history of congestive heart failure, but none with renal disease or diabetes. A single 
participant, who did not have a history of chronic obstructive airways disease, had recently 
had a pneumonic illness which had not required hospitalisation, and for which she was 
receiving amoxycillin at the time of the survey. The titre in this subject was 256. There were 2 
subjects with a titre of 512. Neither had evidence to suggest a recent pulmonary infection. One 
was a smoker with chronic obstructive airways disease, while the other had no medical history 
of note and was a life-long non-smoker. None of those with positive titres was on 
immunosuppressive therapy. 
6. DISCUSSION 
6.1 Study population 
The particpation rate in this study was high (88,4%). This may have been influenced by the 
fact that the study was conducted in old age homes. Residents of an old age home could be 
considered to represent a captive population and may be reluctant to be seen to be different 
from their fellow residents by refusing to participate. This may have resulted in a form of 
selection bias. 
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No data is available on those who refused consent or on those from whom a suitable blood 
specimen could not be obtained. In order to assess non-response bias a questionnaire on each 
of these should have been completed providing demographic details, as well as information as 
to health status, including mental and psychiatric status. It would also have been of value to 
determine why they did not wish to participate. If they had been found to differ from the 
participants in a consistent or systematic way, this too might have allowed analysis for study 
sample bias (non-participant bias). It is possible that subjects with dementia might be more 
likely to refuse to participate, and, as many of the residents of these homes suffered from 
dementia, this may have been one of the reasons for non-participation in this study. Any 
subject with acute confusion, eg due to an illness such as Legionella pneumonia, might be 
similarly uncooperative. Lack of suitable data does not permit verification of this, but it could 
mean that subjects who were ill might have been excluded contributing to falsely low 
prevalence data. 
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The fact that participants in the present study were all residents of old age homes and not 
community dwelling elderly may be of particular relevance. Mycoplasma is spread from person 
to person by infected droplets, but is not highly contagious. Close contact is essential, and the 
prevalence in closed communities is known to be increased (Luby, 1991). An old age home 
could be c~msidered to constitute a closed community especially in the case of the more infinn 
residents who are confined to frail care units and thus live in close proximity to one another. 
This may, in fact, lead to an increased exposure to mycoplasma in old age homes with a 
consequent greater prevalence of mycoplasmal antibodies than in the general community 
dwelling elderly population. It is also possible that longer duration of residence within the 
home may predispose to infection. 
By contrast, Legionella is not spread from person to person, but by inhalation of infected 
water which has been aerosolised (Edelstein & Meyer, 1984 ). The fact that the prevalence of 
Legionella seropositivity in these homes was so low and that there was no clustering of 
positive sera from a single home suggests that a point source of infection within the home 
itself was highly unlikely, and that the infection may have been acquired elsewhere. 
Although the stated objective was to assess antibody prevalence in the elderly in old age 
homes in Cape Town, only those resident in the 4 participating old age homes were included. 
Ideally we would have liked to include elderly black persons in the study sample, but, for the 
reasons given earlier, this was not possible. As a result, no black elderly were included, so the 
sample is not truly representative of the elderly in Cape Town, nor indeed of the old age home 
population, leading to possible sample bias. The generalisability of the results obtained to the 
elderly population of Cape Town as a whole are thus subject to question. For socio-economic 
51 
reasons, black families tend to live in more cramped conditions and the elderly have greater 
exposure to children. This may enhance the likelihood of droplet spread, and may predispose 
to mycoplasma infection in black elderly. In addition, those who were more ill ( eg those who 
had Legionella pneumonia), might have died, and would thus have been excluded from any 
serological survey. Data on those who died are not included. It is thus conceivable that there is 
an underestimation of the prevalence of both mycoplasma and Legionella seropositivity in this 
study. 
6.2 Sample size 
The sample was not random nor a true cluster sample, and sample size was not determined in 
advance. The sample was merely drawn from those in the 4 old age homes who were over 60, 
willing to participate, and from whom blood could be obtained without too much difficulty. 
The sample could thus be described as a "convenience" sample. 
A calculation was done in order to determine what an appropriate size would have been had 
the sample been chosen at random, and assuming an expected frequency of seropositivity of 
2,5%. 
There are no comprehensive data available as to the numbers of people resident in old age 
homes in Cape Town. Data from the Population Census of 1991 were used to determine the 
number of elderly in Cape Town (Table 10). The only figures available were for females aged 
60 and over and for males aged 65 and over. This means that males aged 60 to 65 are not 
included in the calculation, resulting in an underestimation of the population under 
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investigation. A total of 142,322 was obtained of whom 96,738 were female and 45,584 were 
male. A figure of 150,000 was used for the population size in the calculation. 
The Statcalc function of the Epi Info programme was used to do the determination (Appendix 
II). Using a-population size of 150,000 and assuming an expected frequency of 2,5%, a sample 
size of 657 would be needed for a confidence level of99,9%. This is comparable with the 677 
who actually participated in the study. 
6.3 Consent 
Each of the old age homes in which the study was conducted housed a significant number of 
residents who were mentally frail. As a result, it was decided that proxy consent provided by 
the matron or by a relative would suffice where written consent could not be obtained from 
the resident him/herself. The fact that the procedure by which the blood specimen was 
obtained was not an unduly invasive one meant that we did not feel obliged to contact a family 
member in each case where the resident was not competent to give consent. In no case was 
coercion used. However, it remains open to question as to whether the procedure used to 
obtain consent was adequate in all instances. 
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6.4 Methods 
The accuracy and completeness of the medical details on the questionnaire depended to a large 
extent on what appeared in each resident's medical records. For most of the residents, medical 
attention was provided by the district surgeon attending the home or by the doctor at the 
nearest Day Hospital. However, a proportion were cared for by private medical practitioners, 
and, as a group, they tended to make scanty notes in the records held by the home. The 
information that we were able to extract may thus have been lacking in some details causing 
information bias. Private practitioners were not contacted to ensure that such deficiencies did 
not exist. 
6.5 Seropositivity to Mycoplasma pneumoniae 
In this study the antibody titre in a single specimen only was obtained, the purpose being to 
determine exposure to the organism and not to diagnose acute infection. The presence of IgM 
antibodies would normally suggest current or recent infection, although, as mentioned earlier, 
in older persons little or no IgM may be produced (Moule & Caul, 1987; Uldum et al., 1992). 
Only 9 subjects had detectable levels oflgM, and these were low with titres of 16 in 1 and 8 in 
the remaining 8, suggesting that none of these subjects had had an acute or recent infection. 
The low titres could be due to poor antibody production, to waning titres from previous 
infection, or may represent cross-reactivity. 
There were 16 subjects with detectable IgG titres. In 15 the titre was 32 or greater in keeping 
with previous infection at some time in the past, while in 3 the titre was 64 and may represent 
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more recent infection. The fact that IgM titres in these 3 were low (8) or undetectable would 
tend to make current infection unlikely. The single IgG titre of 8 may be insignificant or may 
represent a waning titre from an infection in the more distant past. 
The interpretation of antibody levels is made difficult not only by the cyclical nature of 
mycoplasmal infections, but also by the fact that antibody levels in patients who have had 
mycoplasmal pneumonia may remain elevated for as long as 3 years (Foy et al., 1983). In 
addition, because mycoplasmal infection may be asymptomatic, antibodies to mycoplasma may 
be detected in subjects who have no history of previous mycoplasmal infection. Several studies 
have assessed the prevalence of antimycoplasmal antibodies in healthy members of the 
population (Table 9). Results are difficult to compare because techniques for antibody 
detection vary, as do titres considered positive. However, positivity rates have tended to be 
low with low titres recorded, varying from <1% to 16% at a titre of 64 (Table 9). No study 
has specifically addressed this question in older members of the community, and only 0,4% in 
the current study had a titre of 64, most (2,4%) having a titre of only 8. 
The only other South African study which determined seropositivity to mycoplasma was that 
ofRoss and Harwin (1972) in which 287 blood donors aged 18 to 65 were screened. Using 
the metabolic inhibition technique they found titres of 2:64 in 0, 7%. No indication is given as 
to what proportion of the sample was aged 60 and older. As these were blood donors, it might 
safely be assumed that those in this older age group formed a very small proportion of the 
study population. Selection bias in blood donors would have favoured subjects who had not 
recently had pyrexial illnesses, and would thus have tended to exclude subjects with recent 
acute symptomatic mycoplasmal infection. 
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6.6 Seropositivity to Legionella pneumophila 
Of the few studies in the literature describing seropositivity rates to Legionella, none deals 
specifically with the elderly, although the mean age in the study among medical outpatients by 
Nichol et a.I. (1991) was 67 years (Table 10). The prevalence rate found in our study (mean 
age 78 years) is thus difficult to compare with published reports, since the relative impact of 
the background population prevalence is as yet unknown. 
All 9 sera in this study which were regarded as positive had titres of 128 or above, while in 
only 3 the titre was 256 or greater. No history was taken specifically to elicit symptoms which 
could be attributable to recent Legione//a infection. In any case, most cases of Legione//a 
infection are subclinical or asymptomatic. For that reason, in this study all sera with titres of 
128 or above were regarded as being positive and suggestive of acute or recent infection. 
The epidemiological implications of the seropositivity rates found in this study are open to 
question. Whilst reports indicate that Legionella antibody titres remain elevated for years after 
the acute infection, it is not known whether age has any influence on the antibody response or 
the duration of antibody positivity (Tsai et al., 1979; Nguyen & Yu, 1991; Kirby et al., 1980). 
In this study it is not possible to tell if any of the positive antibody titres was due to a recent 
infection, as this information was not specifically sought. However, one of the subjects was 
receiving treatment for a lower respiratory tract infection and had a titre of 256. This may 
represent a current infection with Legionella. The 2 subjects with the highest titre (512) had 
no history to suggest an acute infection in the recent past. It must be noted, however, that 
demented residents may not complain of feeling unwell, and that manifestations of respiratory 
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tract infection might go unnoticed by the staff It has been shown that in some instances 
positive Legionella titres may be due to cross-reacting antibodies due to Gram-negative 
bacilli, mycoplasma, or chlamydia (Grady & Gilfillan, 1979; Ormsbee et al., 1978; Nguyen & 
Yu, 1991). Since these sera were tested for Mycoplasmapneumoniae, and none had positive 
titres, this J¥ould seem an unlikely explanation. 
Although male sex has been shown to be a risk factor for Legionella, the proportion of males 
with positive titres (2/174 = 1, 14%) is, in fact, smaller than in the females in the study group 
(7/503 = 1,39%). Those with positive titres do not appear to have more chronic illnesses than 
elderly people in general or than the study population as a whole. This would tend to support 
the contention that while these characteristics place people at greater risk for developing 
Legionella pneumonia, subclinical infection may be more closely related to the likelihood of 
environmental exposure to the organism. 
There are 2 South African studies which have assessed seropositivity to Legionella in healthy 
subjects (Table 10). The first is that ofRatshikhopha et al. (1990) in which 456 blood donors 
(mean age 32, 1 years) were screened. The proportion with significant titres was higher than in 
our study with 28,3% having IgG titres :?:64 and 12,5% IgM titres :?:64. 
A similar study was performed among blood donors in Cape Town by de Goveia (1989) and 
submitted as part of an Ml\.1ed thesis. Of the 200 donors screened (ages<20 to >60, 6 being 
:?:60) 8 (4%) had titres :?:64. Of these 2 (a third) were aged 60 or over. 
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Although both these studies used the indirect fluorescent antibody technique using heat killed 
antibody (the same technique as used in this study), the results cannot really be compared. It is 
not evident how many in the study by Ratshikhopha et al. (1990) were aged 60 or older, while 
in the study by de Goveia (1989) only 6 of the 200 fell into this age group. The fact that as 
many as a third of the elderly in the latter study had antibodies to Legionel/a may simply have 
been fortuitous, given the extremely small sample in that age group. Note that in the current 
study only titres :2: 128 were sought. 
6. 7 The role of serology in healthy subjects 
Determining the seropositivity rate to specific organisms among healthy (non-ill) members of 
the community gives an indication of previous exposure to the organism in the community 
(Nichol et al., 1991). It is interesting to note that this background prevalence rate represents 
the false positive rate for a single antibody titre if it is to be used to establish a diagnosis of 
acute infection. The higher the background titre (false positive rate) in the specific population 
being tested, the lower will be the specificity and sensitivity of that test in the particular 
population. 
The indirect fluorescent antibody test was designed to diagnose acute infection, and the 
sensitivity and specificity of the test relate to its ability to do just that. The Centre for Disease 
Control definition of a probable case of acute Legionella infection requires that there be a 
compatible illness plus the demonstration of a single antibody titre to Legionel/a pneumophila 
;?:256. The sensitivity and specificity of a fourfold rise in antibody titre to Legionella 
pneumophila serogroup 1 have been estimated at 80% and 95% respectively (Wilkinson, 
1982; Wilkinson et al., 1983). However, the specificity of a single elevated titre is directly 
related to the background positivity rate for the population from which the patient comes, 
which, as indicated above, represents the false positive rate. 
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In this study the false positive rate for a single titre ~128 would be 1,33%, and so the 
specificity of a single titre ~ 128 in diagnosing acute infection would be 98, 7% ( specificity = 1 -
false positive rate) (Sackett et al., 1985). Hence, in our population a single titre of only 128 
may be regarded as diagnostic. All 9 with positive titres in this study had titres ~128, but only 
one appeared to have acute disease (the subject whose titre was 256). It might under these 
circumstances be presumed that they all had had recent Legionella infection, albeit 
asymptomatic. 
The Zeus indirect fluorescent antibody test (Zeus Scientific Inc.) for IgM antibodies to 
Mycoplasma pneumoniae is 77,3% sensitive and 97,6% specific, while the test for IgG is 
94,4% specific (Zeus Scientific Inc.). The false positive rate for a single IgG titre ~64 in our 
population would be 1,3 3% (3/677), so the specificity of a single titre ~64 would be 98, 7% 
(100 - 1,33). Titres ofigM are very low, but from this study a single titre ~16 (presuming no 
cross-reactivity) would be 99,8% (100 - 0, 15). Hence, it appears that this test is highly 
specific, but not 100% sensitive. 
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7. CONCLUSIONS AND RECOMMENDATIONS 
This is the first study of its type in South Africa which has specifically sought to determine the 
prevalence_ of seropositivity to Legionel/a and mycoplasma in elderly persons. It is recognised 
that this study has several limitations which relate mainly to the choice of sample, and the fact 
that information regarding non-participants was not specifically sought. These factors may 
have introduced bias. The major drawback is that the results obtained, while being applicable 
to the population in which the study was conducted, may not be generalisable to elderly South 
Africans as a whole. However, for the reasons put forward in the Discussion, it is argued that 
the prevalence of Legionel/a seropositivity in this study is likely to be an under-estimate of the 
status of the general South African elderly population, while the direction of bias of the 
seropositivity rate for mycoplasma remains unknown. 
This study has shown that, amongst the elderly in the old age homes studied, the prevalence of 
antibodies to Legionella and mycoplasma is low. This suggests that exposure to infection with 
these 2 agents is not common, and that they do not constitute significant causes of community 
acquired pneumonia in this population. This mitigates against the need for empiric antibiotic 
therapy in most elderly patients presenting with community acquired pneumonia which 
includes antimicrobial agents active against Legionella or mycoplasma, and is in keeping with 
the current recommendation of the South African Pulmonology Society ( 1996) that first-line 
treatment of community acquired pneumonia should be a parenteral second generation 
cephalosporin or co-amoxiclav. However. there are exceptions where infection with one of 
these agents may seem likely, and this may prompt the addition of erythromycin, tetracycline, 
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or another macrolide while seeking serological confirmation of the diagnosis. Features such as 
minimal sputum production, the absence of a predominant organism on Gram stain, prominent 
constitutional symptoms such as headache or fever, ;;\ the presence of extrapulmonary 
manifestations such as diarrhoea, vomiting, arthralgia or myalgia might be suggestive, as 
would failure to respond to treatment with penicillin or a cephalosporin within 48 to 72 hours. 
It must, however, be remembered that elderly patients with bacterial pneumonia may have an 
atypical presentation, especially if the pneumonia is severe. In addition, in our area, 
tuberculosis may present as an acute pneumonia, particularly in old age homes, and may need 
to be excluded. 
As has been indicated earlier, the false positive rate of the indirect fluorescent antibody test for 
these 2 organisms in this population is low, and as a result the specificity of these tests is high. 
This may be of value in making a diagnosis of acute infection with either agent in an elderly 
patient with a compatible clinical picture, in that a positive antibody titre ( even if relatively 
low) might be regarded as being highly specific and may permit a presumptive diagnosis of 
acute infection on a single specimen, although a fourfold rise on paired acute and convalescent 
sera would be the ideal. 
Several areas remain to be elucidated as regards infection with these 2 organisms in the 
elderly. While this study was conducted in old age homes, there is still no clear idea as to the 
level of exposure to Legionella and mycoplasma in the general community dwelling elderly 
population. It is recommended that a community-based survey be undertaken to assess this. 
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While certain aspects of the immunology of these agents is known, much remains to be 
determined, especially with regard to older persons. In particular, studies should be directed at 
investigating the immunoreactivity of the elderly to these 2 agents, as well as determining the 
pattern of antibody response and decay in older persons, as this will assist in interpreting the 
results of ~erology conducted in those presenting with acute disease. 
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TABLE 1: AETIOLOGY OF COMMUNITY ACQUIRED PNEUMONIA IN ADULTS 
Aetiologic Agent (o/•) 
Author Country No. No Mortality 
(mean age Year of Pathogen (%) 
of Cues Fint Second Third Identiited 
subjects) 
(%) 
Blanquer Valencia 510 Pneumococcus Legione/la Mycoplasma 45 6 
(58) -Spain - (45) (14) (4) 
1991 
British Multi centre 453 Pneumococcus Mycoplasma Influenza A 33 6 
Thoracic UK (34) (18) (7) 
Society 1987 
48 
Fang Pittsburgh 359 Pneumococcus H.injluenzae Legionella 41 14 
(62) USA (15) (11) (7) 
1990 
Fine Boston Pneumococcus H.injluenzae Staphylococcus 65 13 
(57) USA (13) (8) (5) 
1990 
Karalus Waikato 92 Pneumococcus Mycoplasma Influenza A 18 7 
(56) New (33) (18) (8) 
Zealand 
1991 
Lim Adelaide 106 Pneumococcus H. injluenzae Entero- 33 10 
(60) Australia (42) (9) bacteriaceae 
1989 8 
Macfarlane Nottingham 127 Pneumococcus Legionella Chlamydia 3 15 
(51) UK (76) (15) (5) 
1982 
Marrie Nova Scotia 57 Aspiration H.inj/uenzae Pneumococcus 30 IO 
(46) Canada (23) (14) (12) 
1985 
Pachon Seville 67 Pneumococcus Legionella 52 21 
(57) Spain (18) (IO) 
1990 
Rello Barcelona 58 Pneumococcus Legionel/a Gram-negative 40 22 
(45) Spain (37) (23) bacilli 
1993 11 
White Bristol 103 Mycoplasma Pneumococcus Influenza A 52 8 
(54) UK (14) (11) (10) 
1981 
Woodhead Nottingham 236 Pneumococcus H.Jnj/uenzae Influenza A 45 3 
(59) UK (36) (10) (6) 
1987 
TABLE 2: AETIOLOGY OF COMMUNITY ACQUIRED PNEUMONIA IN ELDERLY 
Aetiologic Agent (°lo) 
Author Country No. No Mortality 
(mean age Year of Pathogen (•/e) 
of Cases First Second Third Identified 
subjects) 
(%) 
Carr Dublin 127 Pneumococcus H.influenzae B. catarrhalis 39 11 
(77) Ireland (37) (18) (10) 
1991 
Ebright Milwaukee 33 Gram-negative Pneumococcus S.aureus 54 24 
(~65) USA bacilli (18) (6) 
1980 {212 
Garb Springfield 35 Gram-negative Pneumococcus H.injluenzae 20 
(76) Mass USA bacilli (43) (20) 
1978 {57} 
Harper Portland 48 H. injluenzae Pneumococcus Mixed 12 
(78) Oregon (33) (23) (16) 
USA 
1989 
Marrie Novo Scotia 81 Aspiration Cytomegalo- Pneumococcus 54 30 
(77) Canada (9) virus (7) 
1985 9 
Venkatesan Nottingham 73 Pneumococcus H.influenzae lnfluenz.a B 57 33 
(79) UK (30) (7) (7) 
1990 
Verghese Tennessee 32 Gram-negative Pneumococcus H.injluenzae 33 
(-) USA bacilli (34) (28) 
1983 {47} 
TABLE 3: PROPORTION OF CASES OF ADULT COMMUNITY ACQUIRED 
PNEUMONIA CAUSED BY MYCOPLASMA OR LEGIONELLA 
AUTHOR COUNTRY No. of Cases MYCOPLASMA LEGIONELLA 
YEAR % % 
Blanquer Spain 510 14 4 
1991 
British Thoracic UK 453 18 2 
Society 
1987 
Fang USA 359 2 7 
1990 
Karalus New Zealand 92 18 4 
1991 
Lim Australia 106 8 3 
1989 
Maartens RSA 92 1 9 
1994 
Macfarlane UK 127 2 15 
1982 
Marrie Canada 57 2 2 
1985 
Pachon Spain 67 0 10 
1990 
Potgieter RSA 95 1 5 
1992 
Prout RSA 81 10 0 
1983 
White UK 103 14 1 
1981 
TABLE 4: AGE SPECTRUM OF CASES OF MY CO PLASMA PNEUMONIA£ PNEUMONIA 
AUTHOR COUNTRY No. of Cases Percentage (No.) Age (Yrs) 
(AGE RANGE) YEAR 
Ali Norwich 47 400/o (19) <20 
(4-82y) UK 74% (35) <40 
1986 21% (10) >60 
Dular Ottawa 51 65% (33) <20 
(2-59y) Canada 35% (19) >20 
1987 
Mansel Minnesota 148 91% (134) <40 
(3m-77y) USA 9% (14) >40 
1989 
Marrie Nova Scotia 64 91% (58) <65 
Canada 90/o (6) 65+ 
1993 
TABLE 5: MORTALITY RA TES DUE TO MYCOPLASMA OR LEG/ONELL.A 
AUTHOR COUNTRY MYCOPLASMA LEG/ONELL.A 
(YEAR) %MORTALITY %MORTALITY 
Ali UK 3 
(1986) 
Blanquer Spain 0 10 
(1991) 
British Thoracic Soc UK 5 0 
(1987) 
Carr Ireland 0 
(1991) 
England USA 19 
(1981) 
Fang USA 0 17 
(1990) 
Karalus New Zealand 0 0 
(1991) 
Lim Australia 0 0 
(1989) 
Macfarlane UK 0 0 
(1982) 
Mansel USA 0 
(1989) 
Marrie Canada 0 0 
(1985) 
Pachon Spain 0 
(1990) 
Potgieter RSA 0 0 
(1992) 
Prout RSA 0 
(1983) 
Rello Spain 25 
(1993) 
White UK ~ 67 .J 
(1981) 
Woodhead UK 0 16 
(1987) 
TABLE 6: PARTICIPANTS WITH ANTIBODIES TO MYCOPLASMA 






268 32 8 
377 32 
393 32 
397 32 8 
405 32 8 
431 32 8 
536 32 8 
651 32 8 
660 32 8 
198 64 
520 64 8 
521 64 
661 16 
TABLE 7: PARTICIPANTS WITH ANTIBODIES TO LEGIONELLA 











TABLE 8: NUMBERS OF ELDERLY IN CAPE TOWN 












































COUNTRY STUDY SUBJECTS 
SIZE (AGE) 
Sweden 422 Blood donors 
(16-76) 






New Zealand 1461 Blood donors 
(16-65) 
South Africa 287 Blood donors 
(18-65) 
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Population Survey or Descriptive Study Using Random (Not Cluster) Sampling 
Population Size 150,000 
Expected Frequency 2.50% 
Worst Acceptable 0.05% 







Formula: Sample Size= n/(1-(n/population)) 
n=Z*Z(P(l-P))/(D*D) 
Reference: Kish & Leslie, Survey Sampling, John Wiley & Sons, NY, 1965. 
